These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

953 related articles for article (PubMed ID: 19185651)

  • 1. Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.
    Marijon E; Trinquart L; Otmani A; Waintraub X; Kacet S; Clémenty J; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Feb; 157(2):391-397.e1. PubMed ID: 19185651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors for short-term progressive heart failure death in New York Heart Association II patients implanted with a cardioverter defibrillator--the EVADEF study.
    Marijon E; Trinquart L; Otmani A; Leclercq C; Fauchier L; Chevalier P; Klug D; Defaye P; Lellouche N; Mansourati J; Deharo JC; Sadoul N; Anselme F; Maury P; Davy JM; Extramiana F; Hidden-Lucet F; Probst V; Bordachar P; Mansour H; Chauvin M; Jouven X; Lavergne T; Chatellier G; Le Heuzey JY;
    Am Heart J; 2010 Apr; 159(4):659-664.e1. PubMed ID: 20362726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk study.
    Koller MT; Schaer B; Wolbers M; Sticherling C; Bucher HC; Osswald S
    Circulation; 2008 Apr; 117(15):1918-26. PubMed ID: 18391108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced ejection fraction, sudden cardiac death, and heart failure death in the mode selection trial (MOST): implications for device selection in elderly patients with sinus node disease.
    Sweeney MO; Hellkamp AS; Ellenbogen KA; Lamas GA
    J Cardiovasc Electrophysiol; 2008 Nov; 19(11):1160-6. PubMed ID: 18554201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population).
    Zareba W; Piotrowicz K; McNitt S; Moss AJ;
    Am J Cardiol; 2005 Jun; 95(12):1487-91. PubMed ID: 15950580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates and predictors of appropriate implantable cardioverter-defibrillator therapy delivery: results from the EVADEF cohort study.
    Otmani A; Trinquart L; Marijon E; Lavergne T; Waintraub X; Lepillier A; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Aug; 158(2):230-237.e1. PubMed ID: 19619699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II.
    Goldenberg I; Moss AJ; Hall WJ; McNitt S; Zareba W; Andrews ML; Cannom DS;
    Circulation; 2006 Jun; 113(24):2810-7. PubMed ID: 16769917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival of patients with heart failure and ventricular conduction delay treated with cardiac resynchronization therapy.
    Auricchio A; Metra M; Gasparini M; Lamp B; Klersy C; Curnis A; Fantoni C; Gronda E; Vogt J;
    Am J Cardiol; 2007 Jan; 99(2):232-8. PubMed ID: 17223424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study.
    Salerno-Uriarte JA; De Ferrari GM; Klersy C; Pedretti RF; Tritto M; Sallusti L; Libero L; Pettinati G; Molon G; Curnis A; Occhetta E; Morandi F; Ferrero P; Accardi F;
    J Am Coll Cardiol; 2007 Nov; 50(19):1896-904. PubMed ID: 17980258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators: design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study.
    Bellocci F; Biasucci LM; Gensini GF; Padeletti L; Raviele A; Santini M; Giubilato G; Landolina M; Biondi-Zoccai G; Raciti G; Sassara M; Castro A; Kheir A; Crea F
    J Cardiovasc Med (Hagerstown); 2007 Apr; 8(4):293-9. PubMed ID: 17413310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Freudenberger RS; Hellkamp AS; Halperin JL; Poole J; Anderson J; Johnson G; Mark DB; Lee KL; Bardy GH;
    Circulation; 2007 May; 115(20):2637-41. PubMed ID: 17485579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias.
    Healey JS; Hallstrom AP; Kuck KH; Nair G; Schron EP; Roberts RS; Morillo CA; Connolly SJ
    Eur Heart J; 2007 Jul; 28(14):1746-9. PubMed ID: 17283003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Olshansky B; Wood F; Hellkamp AS; Poole JE; Anderson J; Johnson GW; Boineau R; Domanski MJ; Mark DB; Lee KL; Bardy GH;
    Am Heart J; 2007 Jun; 153(6):1089-94. PubMed ID: 17540216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower body mass index and atrial fibrillation as independent predictors for mortality in patients with implantable cardioverter defibrillator.
    Schernthaner C; Pichler M; Strohmer B
    Croat Med J; 2007 Feb; 48(1):59-67. PubMed ID: 17309140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum.
    Bloomfield DM; Steinman RC; Namerow PB; Parides M; Davidenko J; Kaufman ES; Shinn T; Curtis A; Fontaine J; Holmes D; Russo A; Tang C; Bigger JT
    Circulation; 2004 Oct; 110(14):1885-9. PubMed ID: 15451804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of mortality events in the Multicenter Automatic Defibrillator Implantation Trial (MADIT-II).
    Greenberg H; Case RB; Moss AJ; Brown MW; Carroll ER; Andrews ML;
    J Am Coll Cardiol; 2004 Apr; 43(8):1459-65. PubMed ID: 15093884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.
    Hohnloser SH; Kuck KH; Dorian P; Roberts RS; Hampton JR; Hatala R; Fain E; Gent M; Connolly SJ;
    N Engl J Med; 2004 Dec; 351(24):2481-8. PubMed ID: 15590950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arrhythmic death in implantable cardioverter defibrillator patients: a long-term study over a 10 year implantation period.
    Duray GZ; Schmitt J; Richter S; Israel CW; Hohnloser SH
    Europace; 2009 Nov; 11(11):1462-8. PubMed ID: 19797255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Italian Implantable Cardioverter-Defibrillator Registry. A survey of the national activity during the years 2001-2003.
    Proclemer A; Ghidina M; Cicuttini G; Gregori D; Fioretti PM
    Ital Heart J; 2005 Mar; 6(3):272-80. PubMed ID: 15875520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.